Bafna Pharmaceuticals Limited

BSE: BAFNAPH532989ISIN INE878I01022

Healthcare
Pharmaceuticals

Share price

₹445.20+8.70 (+1.99%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹487.45
52W low: ₹95.00
Off 52W high: -8.67%
1M return: +13.37%
3M return: +57.31%
6M return: +223.78%
1Y return: +161.50%
20D avg volume: 9,037
50 DMA: ₹372.38
200 DMA: ₹214.76

Key ratios Standalone

Market cap: ₹1,053 Cr
Current price: ₹445.20
52W high / low: ₹487.45 / ₹95.00
Face value: ₹10.00
P/E: 135.32
P/B: 12.73
EPS (TTM): ₹3.29
Book value / share: ₹34.97
ROE: 9.41%
ROCE: 12.40%
Operating margin: 10.51%
Net margin: 0.28%
Debt / equity: 0.39
Net debt: ₹35.41 Cr
Interest cover: 4.00
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 100.7 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	26.58	42.24	38.29	35.47	34.62	39.06	33.19	40.32	33.29	41.40	28.44	40.68
	1.91	1.76	1.22	1.18	0.60	1.02	0.19	1.02	0.51	0.52	0.98	0.16
	28.49	44.00	39.51	36.65	35.22	40.09	33.38	41.34	33.79	41.91	29.42	40.84
	28.42	41.38	37.67	33.52	31.83	36.99	32.42	38.73	34.17	40.46	32.36	38.35
	14.31	21.39	24.00	18.56	17.56	17.43	16.87	21.82	18.37	23.79	16.00	19.67
	0.00	0.00	0.00	0.63	0.00	0.00	—	—	—	1.65	2.67	1.60
	5.62	5.44	5.35	5.49	5.64	5.58	5.26	5.06	5.14	5.38	4.53	4.85
	0.94	1.03	0.86	0.86	0.91	0.82	0.64	0.62	0.65	0.68	0.58	0.44
	1.78	1.66	1.57	1.47	1.37	0.22	1.66	1.57	1.44	1.27	1.27	1.24
	7.47	8.89	7.68	7.63	6.58	8.82	1.24	3.72	1.84	4.90	2.70	3.03
	0.08	2.62	1.84	3.12	3.39	3.10	0.96	2.62	-0.38	1.46	-2.94	2.48
	0.00	0.00	0.00	0.00	0.00	-1.79	-0.01	—	-0.34	—	—	—
	0.08	2.62	1.84	3.12	3.39	1.31	0.95	2.62	-0.72	1.46	-2.94	2.48
	0.00	-0.13	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	0.08	2.75	1.84	3.12	3.39	1.31	0.95	2.62	-0.72	1.46	-2.94	2.48
	0.03	1.16	0.78	1.32	1.43	0.55	0.40	1.11	-0.31	0.62	-1.24	1.05
Key metrics
	2.80	5.31	4.27	5.45	5.67	2.35	3.25	4.81	1.37	3.41	-1.09	4.16
	10.50%	12.60%	11.20%	15.40%	16.40%	6.00%	9.80%	11.90%	4.10%	8.20%	-3.80%	10.20%
	0.30%	6.50%	4.80%	8.80%	9.80%	3.40%	2.90%	6.50%	-2.20%	3.50%	-10.30%	6.10%
	—	3.10%	—	3.50%	—	2.10%	—	—	—	—	—	—
	-23.20%	8.10%	15.40%	-12.00%	4.00%	-5.70%	16.70%	-0.90%	—	—	—	—
	-97.60%	109.90%	93.70%	19.10%	570.80%	-10.30%	132.30%	5.60%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	142.58	150.62	145.86	152.47	115.35	85.14
	6.07	4.76	2.74	3.52	3.27	2.10
	148.65	155.37	148.60	155.99	118.62	87.24
	140.99	144.40	142.30	148.64	107.01	79.94
	78.26	82.14	74.49	79.01	59.57	53.06
	0.63	0.00	0.00	12.57	6.41	—
	21.90	21.92	21.03	19.03	15.87	14.50
	3.69	3.66	2.73	2.29	2.04	0.79
	6.48	6.07	4.89	5.00	5.33	5.49
	31.67	30.78	32.72	15.42	7.17	7.86
	7.66	10.97	6.30	7.35	11.62	7.31
	0.00	0.00	-2.15	—	—	-2.16
	7.66	10.97	4.15	7.35	11.62	5.15
	-0.13	-0.13	0.00	—	0.28	—
	7.79	11.10	4.15	7.35	11.34	5.15
	3.29	4.69	1.76	3.11	4.86	2.17
Key metrics
	17.83	20.70	11.77	14.64	18.99	11.43
	12.51%	13.70%	8.10%	9.60%	16.50%	13.40%
	5.46%	7.40%	2.80%	4.80%	9.80%	6.00%
	—	12.40%	6.80%	—	—	—
	-3.13%	3.30%	-4.30%	32.20%	35.50%	—
	-5.80%	167.50%	-43.50%	-35.20%	120.20%	—
	—	-9.53	0.28	—	—	—
	—	1.38	5.33	—	—	—
	—	0.39	0.33	—	—	—
	—	35.41	24.77	—	—	—
	—	100.7	93.4	—	—	—
Balance sheet
	—	175.53	153.08	—	—	—
	—	89.65	84.73	—	—	—
	—	2.02	3.43	—	—	—
	—	43.93	40.17	—	—	—
	—	28.90	28.09	—	—	—
	—	12.90	12.71	—	—	—
	—	81.79	58.78	—	—	—
	—	31.29	30.95	—	—	—
	—	57.19	51.85	—	—	—
	—	37.43	28.20	—	—	—
	—	19.65	14.17	—	—	—
	—	17.78	14.03	—	—	—
	—	96.15	84.81	—	—	—
Cash flow
	—	15.37	22.14	—	—	—
	—	-22.40	-21.16	—	—	—
	—	5.62	1.06	—	—	—
	—	24.90	21.86	—	—	—

Compounded growth

Sales CAGR 3Y: +9.30%
Sales CAGR 5Y: —
Profit CAGR 3Y: -0.71%
Profit CAGR 5Y: —
Sales YoY (TTM): -3.13%
Profit YoY (TTM): -5.80%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 75.01%

Quarter	September 2026	June 2026
Promoter %	75.01%	75.01%

Holder	Type	Holding	Previous	Change
SRJR LIFESCIENCES LLP	Promoter	74.57%	74.57%	0.00%
CULLINAN OPPORTUNITIES FUND VCC-CULLINAN OPPORTUNITIES INCORPORATED VCC SUB FUND 1	Public	3.21%	—	—
M7 GLOBAL FUND PCC-CELL DEWCAP FUND	Public	3.12%	3.12%	0.00%
ZEAL GLOBAL OPPORTUNITIES FUND	Public	3.01%	3.01%	0.00%
ALPANA MUNDRA	Public	2.73%	2.73%	0.00%
MONARCH NETWORTH FINSERVE PRIVATE LIMITED	Public	1.35%	1.35%	0.00%
GUTTIKONDA VARA LAKSHMI	Public	1.29%	1.29%	0.00%
P PARAS BAFNA	Promoter	0.21%	0.21%	0.00%
NAVIN BAFNA	Promoter	0.18%	0.18%	0.00%
MAHAVEER CHAND BAFNA	Promoter	0.03%	0.03%	0.00%
AMRI BAI BAFNA	Promoter	0.01%	0.01%	0.00%
SASIKALA BAFNA	Promoter	0.01%	0.01%	0.00%
MAHAVEER CHAND BAFNA HUF	Promoter	0.00%	0.00%	0.00%
CHETNA BAFNA	Promoter	0.00%	0.00%	0.00%
PARAS BAFNA	Promoter	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Bafna Pharmaceuticals Limited S	1,053	445.20	135.32	12.40%	-3.13% TTM	-5.80% TTM	+161.50%

Filings & corporate actions

Recent announcements

Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 202612 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation for Closure of Trading Window26 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
We herewith enclose the Voting Results of the 31st Annual General Meeting of the Company held on September 11, 2026 along with the Scrutinizer Report.11 Sep 2026 · AGM/EGM / AGM
We herewith enclose the Outcome / Proceedings of the 31st Annual General Meeting of the Company held on September 11, 2026.11 Sep 2026 · AGM/EGM / AGM
We herewith enclose the Newspaper Publication for the 31st Annual General Meeting of the Company published in ''Business Standard'' and ''Makkal Kural'' on August 20, 2026.21 Aug 2026 · Company Update / Newspaper Publication
We herewith enclose the Notice of 31st Annual General Meeting of the Company scheduled to be held on Friday, September 11, 2026 at 10.00 A.M along with the Annual Report of the Company ....19 Aug 2026 · AGM/EGM / AGM
We herewith enclose the Annual Report of the Company for the F.Y 2025-2026.19 Aug 2026 · Others / Reg. 34 (1) Annual Report
Newspaper Publication for the Unaudited Financial Results of the Company for the Quarter ended June 30, 2026 as published in ''Business Standard'' and ''Makkal Kural'' on August 13, 2026.14 Aug 2026 · Company Update / Newspaper Publication
We herewith enclose the intimation for Book Closure and Cut-Off dates for the purpose of 31st Annual General Meeting of the Company.13 Aug 2026 · Corp. Action / Book Closure
We hereby inform that the 31st Annual General Meeting (AGM) of the Company is scheduled to be held on Friday, September 11, 2026 at 10.00 A.M through Video Conferencing (VC) / Other Audio ....13 Aug 2026 · AGM/EGM / AGM
We herewith enclose the Unaudited Financial Results for the Quarter ended June 30, 2026 as approved by the Board of Directors in its meeting held on August 11, 2026.11 Aug 2026 · Result / Financial Results
We hereby inform you that the Board of Directors in their meeting held on August 11, 2026 inter-alia considered and approved i) Unaudited Financial Results of the Company for the Quarter ....11 Aug 2026 · Board Meeting / Outcome of Board Meeting
Bafna Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve the Un-Audited Financial ....5 Aug 2026 · Board Meeting / Board Meeting
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended June 30, 2026.9 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation for Closure of Trading Window26 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Intimation for retirement of Mr. Navin Kumar (DIN: 08778662) as an Independent Director of the Company upon completion of his first term, with effect from close of business hours on June 22, 2026.22 Jun 2026 · Company Update / Change in Directorate
Intimation for retirement of Mr. Navin Kumar (DIN: 08778662) as an Independent Director of the Company upon completion of his first term, with effect from close of business hours on June 22, 2026.22 Jun 2026 · Company Update / Retirement
Newspaper Publication for the Audited Financial Results of the Company for the Quarter & Year ended March 31, 2026 as published in "Financial Express" and "Makkal Kural" on May 31, 2026.1 Jun 2026 · Company Update / Newspaper Publication
We herewith enclose the Audited Financial Results of the Company along with the Statutory Auditor''s Report for the Quarter and Year ended March 31, 2026, as approved by the Board of Directors ....29 May 2026 · Result / Financial Results
We hereby inform you that the Board of Directors in their meeting held on May 29, 2026 inter-alia considered and approved the Audited Financial Results of the Company along with the Auditor's ....29 May 2026 · Board Meeting / Outcome of Board Meeting
Bafna Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve the Audited Financial ....21 May 2026 · Board Meeting / Board Meeting
We hereby submit our response to the Clarification sought by the Stock Exchange regarding the movement in the Share Price of the Company.15 Apr 2026 · Company Update / General
The Exchange has sought clarification from Bafna Pharmaceuticals Ltd on April 13, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....13 Apr 2026 · Company Update / Clarification
Certificate under Regulation 74(5) of SEBi (DP) Regulations, 2018 for the Quarter ended March 31, 2026.13 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
The Board of Directors of the Company in the Meeting held on March 27, 2026 has inter-alia considered and approved: (i) The appointment of M/s. K. S. Rao & Co., Chartered Accountants, Chennai ....27 Mar 2026 · Others / Outcome without intimation
Intimation for Closure of Trading Window.26 Mar 2026 · Insider Trading / SAST / Closure of Trading Window
We hereby submit our response to the clarification sought by the Stock Exchange regarding the movement in the share price of the Company.24 Mar 2026 · Company Update / General
The Exchange has sought clarification from Bafna Pharmaceuticals Ltd on March 23, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....23 Mar 2026 · Company Update / Clarification
Newspaper Publication for the Unaudited Financial Results of the Company for the Quarter and Nine-Months ended December 31, 2025 as published in "Business Standard" and "Makkal Kural" on ....14 Feb 2026 · Company Update / Newspaper Publication
The Board of Directors of the Company in their Meeting held on February 11, 2026 has inter-alia considered and approved the Un-Audited Financial Results of the Company along with the Limited ....11 Feb 2026 · Result / Financial Results
The Board of Directors of the Company in the Meeting held on February 11, 2026 has inter-alia considered and approved the Unaudited Financial Results of the Company along with the Limited ....11 Feb 2026 · Board Meeting / Outcome of Board Meeting
Bafna Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 ,inter alia, to consider and approve the Un-Audited Financial ....5 Feb 2026 · Board Meeting / Board Meeting
We hereby inform you that the Outlook of the Credit Ratings assigned to the Bank loan facilites of the Company has been revised by ICRA Limited.23 Jan 2026 · Company Update / Credit Rating
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the Quarter ended December 31, 2025.9 Jan 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation for Closure of Trading Window.26 Dec 2025 · Insider Trading / SAST / Closure of Trading Window
We hereby enclose the Newspaper publication of the extract of the Unaudited Financial Results of the Company for the Quarter and Half Year ended September 30, 2025, as published in "Business ....14 Nov 2025 · Company Update / Newspaper Publication
The Board of Directors of the Company in the Meeting held on November 11, 2025 has inter-alia considered and approved the Unaudited Financial Results of the Company along with the Limited ....11 Nov 2025 · Result / Financial Results
The Board of Directors of the Compant in the meeting held on November 11, 2025 has inter-alia considered and approved the Unaudited Financial Results of the Company along with the Limited ....11 Nov 2025 · Board Meeting / Outcome of Board Meeting
Bafna Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2025 ,inter alia, to consider and approve the Un-Audited Financial ....6 Nov 2025 · Board Meeting / Board Meeting
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the Quarter ended September 30, 2025.10 Oct 2025 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Board meetings

11 Aug 2026 Board Meeting - Financial Results